Literature DB >> 24820349

HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.

Fred M Kusumoto1, Hugh Calkins2, John Boehmer3, Alfred E Buxton4, Mina K Chung5, Michael R Gold6, Stefan H Hohnloser7, Julia Indik8, Richard Lee9, Mandeep R Mehra10, Venu Menon5, Richard L Page11, Win-Kuang Shen12, David J Slotwiner13, Lynne Warner Stevenson14, Paul D Varosy15, Lisa Welikovitch16.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24820349     DOI： 10.1016/j.jacc.2014.04.008

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  20 in total

1.  Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.

Authors:  Nisha Bansal; Adam Szpiro; Kristi Reynolds; David H Smith; David J Magid; Jerry H Gurwitz; Frederick Masoudi; Robert T Greenlee; Grace H Tabada; Sue Hee Sung; Ashveena Dighe; Alan S Go
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

Review 2.  Use of the Wearable Cardioverter Defibrillator in High-Risk Populations.

Authors:  Madhab Lamichhane; Abdul Safadi; Phani Surapaneni; Negar Salehi; Ranjan K Thakur
Journal:  Curr Cardiol Rep       Date:  2016-08       Impact factor: 2.931

3.  The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients.

Authors:  Julia W Erath; Mate Vamos; Abdul Sami Sirat; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2016-11-25       Impact factor: 5.460

4.  Cognitive performance in patients with implantable cardioverter defibrillators: Associations with objective sleep duration, age and anxiety.

Authors:  Ashley F Curtis; Alicia J Roth; Samuel F Sears; Jamie B Conti; Richard B Berry; Joseph M Dzierzewski; Himangshu Rathinakumar; Christina S McCrae
Journal:  J Sleep Res       Date:  2018-12-13       Impact factor: 3.981

Review 5.  From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies.

Authors:  Nosheen Reza; Kiran Musunuru; Anjali Tiku Owens
Journal:  Curr Heart Fail Rep       Date:  2019-10

6.  Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients.

Authors:  Sana M Al-Khatib; Jennifer M Gierisch; Matthew J Crowley; Remy R Coeytaux; Evan R Myers; Amy Kendrick; Gillian D Sanders
Journal:  J Gen Intern Med       Date:  2015-12       Impact factor: 5.128

Review 7.  State-of-the-art narrative review: multimodality imaging in electrophysiology and cardiac device therapies.

Authors:  Balint Laczay; Divyang Patel; Richard Grimm; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

8.  Opsin spectral sensitivity determines the effectiveness of optogenetic termination of ventricular fibrillation in the human heart: a simulation study.

Authors:  Thomas V Karathanos; Jason D Bayer; Dafang Wang; Patrick M Boyle; Natalia A Trayanova
Journal:  J Physiol       Date:  2016-04-24       Impact factor: 5.182

9.  Sudden cardiac arrest and ventricular arrhythmias following first type I myocardial infarction in the contemporary era.

Authors:  Mustapha Amin; Danesh Kella; Ammar M Killu; Deepak Padmanabhan; David O Hodge; Michael A Golafshar; Alanna M Chamberlain; Justin Z Lee; Win-Kuang Shen; Paul A Friedman; Samuel J Asirvatham; Véronique L Roger; Bernard J Gersh; Siva K Mulpuru
Journal:  J Cardiovasc Electrophysiol       Date:  2019-10-17

10.  Wideband LGE MRI permits unobstructed viewing of myocardial scarring in a patient with an MR-conditional subcutaneous implantable cardioverter-defibrillator.

Authors:  Amir Ali Rahsepar; Jeremy D Collins; Bradley P Knight; KyungPyo Hong; James C Carr; Daniel Kim
Journal:  Clin Imaging       Date:  2018-05-04       Impact factor: 1.605
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.